
    
      The objectives of this study are to evaluate the effectivity and the safety of thalidomide in
      patients with disseminated MALT lymphoma or at relapse following HP-eradication, or
      chemotherapy or radiation. It is a phase II prospective single arm study with a target sample
      size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum
      duration of 6 months.
    
  